Search
Corydalis ambigua tuber
go.drugbank.com/drugs/DB14279ApprovedCorydalis ambigua tuber is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Lonicera caprifolium flower
go.drugbank.com/drugs/DB14280ApprovedLonicera caprifolium flower is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Larix sibirica wood
go.drugbank.com/drugs/DB14289ApprovedWithdrawnLarix sibirica wood is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Apricot kernel oil
go.drugbank.com/drugs/DB14324ApprovedApricot kernel oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Azadirachta indica leaf
go.drugbank.com/drugs/DB14352ApprovedAzadirachta indica leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mibefradil
go.drugbank.com/drugs/DB01388ApprovedWithdrawnMibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
Otelixizumab
go.drugbank.com/drugs/DB05496InvestigationalOtelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance
Nadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigational[A255106,L44381] Nadofaragene firadenovec also has a manageable adverse event profile. Compared to [pembrolizumab], a smaller proportion of patients experienced grade 3-4 adverse events (4% vs 12.7%). … [A255111] Nadofaragene firadenovec is formulated with an excipient (Syn-3) that facilitates gene transfer across the urothelium and promotes the transduction of IFNα2b.
Categories: Complex MixturesAvapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigational[A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464] … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal
Cyromazine
go.drugbank.com/drugs/DB20549ExperimentalCyromazine is a small molecule drug. Cyromazine has a monoisotopic molecular weight of 166.1 Da.
Categories: Compounds used in a research, industrial, or household setting